Project description DEENESFRITPL Nanoparticle-based, non-invasive chronic inflammation biomarkers Treatment of unresolved chronic inflammation that leads to the development of many diseases, including cancer, cardiovascular diseases, autoimmune diseases, neurological diseases and rheumatoid arthritis, has to involve longitudinal image-based characterisation of the process. There is an unmet need for non-invasive diagnostic technology that can be used in conjunction with conventional bio-fluid and biopsy markers. This is particularly important in cases when treatment requires long-term preventative lifestyle changes. The EU-funded Unusual-IV project aims to develop clinical non-invasive, nanoparticle-based biomarkers of inflammation that can help in diagnostics, prediction of the outcome, and the assessment of the response to therapy or preventative strategy. Show the project objective Hide the project objective Objective "Cancer. Cardiovascular disease. Autoimmune disease. Neurological disease. Rheumatoid arthritis. What do these diseases have in common? -Chronic inflammation.In recognition of this, the NIH organised a focus session on the current clinical needs around inflammation in 2019, stating “Tools to locate and monitor inflammation are critical for developing effective interventions to arrest inflammation and promote its resolution. Clinical speakers described their needs for image‐based capabilities ... to guide treatment planning and undertake necessary interventions…All speakers agreed that multiple inflammatory measures should be acquired longitudinally to comprehend the dynamics of unresolved inflammation that leads to disease development.” As an example, atherosclerosis- the #1 killer in developed countries- is now known to be a chronic inflammatory disease . Mounting clinical evidence suggests that effective treatment requires a reduction in both LDL levels (cholesterol) and underlying inflammation. However, a simple reduction in inflammation, measured by serum markers, has not proven successful in the clinic . Thus, as also found by the NIH workshop, treatment plans must take into account the inflammation status in the vessel walls in a longitudinal manner, which cannot be measured by blood tests.This is no small task, as chronic inflammation is often asymptomatic until disease has developed. Pubmed has over 36,000 review articles on chronic inflammation. The ultimate goal is to have clinical noninvasive biomarkers of inflammation that can help in diagnosis, predict outcome and assess response to therapy or preventative strategy.Overall, there is an unmet need to noninvasively diagnose inflammation, that can be used in conjunction with conventional biofluid and biopsy markers. This is particularly the case when treatment includes longterm preventative lifestyle changes. Noninvasive clinical imaging could be the solution." Fields of science medical and health sciencesclinical medicinerheumatologymedical and health scienceshealth sciencesinflammatory diseasesmedical and health sciencesclinical medicinecardiologycardiovascular diseasesarteriosclerosismedical and health sciencesbasic medicineimmunologyautoimmune diseasesmedical and health sciencesclinical medicineoncology Keywords inflammation imaging nanoparticles clinical trials personalised medicine Programme(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Topic(s) ERC-2020-POC - Call for proposals for ERC Proof of Concept Grant Call for proposal ERC-2020-PoC See other projects for this call Funding Scheme ERC-POC - Proof of Concept Grant Coordinator CENYA IMAGING B.V. Net EU contribution € 150 000,00 Address Tweede kostverlorenkade 11h 1052RK Amsterdam Netherlands See on map Region West-Nederland Noord-Holland Groot-Amsterdam Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 Beneficiaries (1) Sort alphabetically Sort by Net EU contribution Expand all Collapse all CENYA IMAGING B.V. Netherlands Net EU contribution € 150 000,00 Address Tweede kostverlorenkade 11h 1052RK Amsterdam See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region West-Nederland Noord-Holland Groot-Amsterdam Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00
